Attrition Reducing Technologies (ART)


Accelera is able to offer integrated preclinical profiling platforms called Attrition Reducing Technologies (ART) in the area of ADME/Tox, designed to accelerate the lead optimisation phase. ART allows sponsors to identify the most promising drug candidates at an early stage, while at the same time de-prioritise those with a high risk of failure during the development phase.

---